-
2023-507419-37-00
5
2020-06-25
Plasma cell myeloma
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2024-511940-20-00
5
2020-02-05
Parkinson's disease
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2023-508526-10-00
7
2019-10-01
Malignant solid tumors:
Patients with relapsed or refractory, advanced
-
2022-502616-37-00
9
2019-07-30
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
-
2024-514274-46-00
5
2019-06-21
Solid Tumors
-
2023-509216-28-00
4
2019-05-27
Generalized Pustular Psoriasis
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-506733-30-00
4
2019-05-16
Multiple Myeloma relapsed and/or refractory
-
2024-513396-41-00
5
2019-05-15
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2024-510985-17-00
4
2019-03-14
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2024-511204-16-00
5
2019-01-23
Metastatic breast cancer
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2023-510517-26-00
9
2018-10-26
Acute Myeloid Leukemia
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2023-507657-15-00
5
2018-09-13
Ulcerative Colitis
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2024-512212-21-00
5
2017-11-28
Advanced hepatocellular carcinoma (HCC)